ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI Pharmaceuticals (ANIP) reported strong Q3 2025 results. Net revenues were $227.8 million, up from $148.3 million a year ago. Net income was $26.6 million versus a loss of $24.2 million, and diluted EPS was $1.13. Operating income reached $36.2 million, helped by higher sales in Rare Disease and Brands, especially Cortrophin Gel and the addition of ILUVIEN and YUTIQ.
Year-to-date, net revenues were $636.3 million versus $423.8 million. Operating cash flow was $154.9 million. Cash and cash equivalents were $262.6 million as of September 30, 2025. The company completed the Alimera acquisition in 2024 and in March 2025 expanded ILUVIEN’s U.S. label to include NIU-PS, shifting U.S. promotion from YUTIQ to ILUVIEN. As of October 31, 2025, there were 22,458,168 shares of common stock outstanding.
ANI Pharmaceuticals, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025. The company announced these results in a press release dated November 7, 2025, which is included as Exhibit 99.1. The report clarifies that the information about these quarterly results is being furnished rather than filed, meaning it is not subject to certain liability provisions under securities law unless specifically incorporated into other filings.
ANI Pharmaceuticals (ANIP) reported an insider transaction on a Form 4. Senior Vice President, General Counsel & Secretary Meredith W. Cook sold 400 shares of common stock on 10/13/2025 at $90.09 per share under a Rule 10b5-1 trading plan adopted on September 17, 2024.
Following the sale, Cook beneficially owns 75,674 shares, held directly. This filing reflects routine insider activity disclosed for transparency.
ANI Pharmaceuticals, Inc. disclosed that all of its Series A Convertible Preferred Stock held by Ampersand 2020 Limited Partnership has been converted into common stock. Ampersand originally purchased 25,000 Preferred Shares in 2021 for an aggregate $25 million, with the shares carrying a 6.50% cumulative dividend and conversion features set out in a Certificate of Designation.
On August 14, 2025, Ampersand optionally converted 5,000 Preferred Shares into 120,580 common shares at a conversion price of $41.4662 per share. On September 26, 2025, after specified stock price conditions were met, ANI mandatorily converted the remaining 20,000 Preferred Shares into 482,320 common shares at the same conversion price.
In total, the conversions exchanged all 25,000 Preferred Shares for 602,900 common shares, leaving no Preferred Shares outstanding. The common shares issued in these exchanges relied on the Section 3(a)(9) exemption under the Securities Act for transactions with existing security holders without paid solicitation.
ANI Pharmaceuticals officer Krista Davis reported a sale of 1,000 shares of ANIP common stock on 09/19/2025 at a price of $98.04 per share. The sale was executed under a Rule 10b5-1 trading plan adopted August 23, 2024. After the transaction, the reporting person beneficially owns 60,186 shares, held directly. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and records the transaction as a routine, preplanned disposition under the company insider trading plan.
Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals (ANIP), reported a tax-withholding disposition tied to the vesting of restricted stock. On 09/12/2025 she disposed of 1,710 shares of common stock at a price of $97.71 per share; following the transaction she beneficially owns 61,186 shares. The filing notes those shares were withheld to satisfy tax obligations related to the vesting of 4,108 previously granted restricted shares.
The Form 4 was signed via attorney-in-fact on 09/15/2025. This is a routine, non-derivative withholding to cover taxes on vested restricted stock rather than an open-market sale or a new transfer of ownership.
Meredith W. Cook, Senior Vice President, General Counsel & Secretary of Ani Pharmaceuticals (ANIP), reported a sale of 400 shares of the company on 09/12/2025 at a price of $98.42 per share. After the transaction she beneficially owned 76,074 shares. The filing states the sale was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on 09/17/2024, indicating the trade followed an automated plan rather than an ad‑hoc decision. The Form 4 was signed by Ms. Cook on 09/15/2025.
ANI Pharmaceuticals, Inc. filed a current report noting that President & CEO Nikhil Lalwani and the executive leadership team will present at two upcoming investor conferences in New York City. They are scheduled to speak at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025.
The company prepared an updated investor presentation for these events, dated September 2025, and may use it in future meetings with investors and analysts. This presentation is provided as Exhibit 99.1 and is furnished, rather than filed, meaning it is not subject to certain liability provisions under securities laws unless specifically incorporated into other filings.
Antonio R. Pera, a director of ANI Pharmaceuticals, Inc. (ANIP), reported a sale of 7,292 shares of the company on 09/03/2025 at a price of $94.94 per share. After the transaction, Mr. Pera beneficially owned 22,660 shares. The Form 4 was signed by an attorney-in-fact and filed following the transaction.
Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 7,292 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $692,270.40 and stated approximate sale date of 09/03/2025. The filer identifies prior restricted stock acquisitions of 3,000 shares on 04/27/2023 and 4,292 shares on 03/23/2022, both received from the issuer, and discloses a sale during the past three months of 5,421 shares for $486,406.81 on 08/20/2025. The form includes the standard representation that the seller is not aware of any undisclosed material adverse information.